IDH1 and infantile convulsions and choreoathetosis: A recent phase 3 clinical trial of the IDH1 inhibitor ivosidenib in patients with advanced iCCA has shown promising results in increasing overall survival, and the FDA has approved its use in previously treated IDH1-mutated iCCA patients (143, 144).